Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1918 safety and PK/PD in healthy subjects
NCT05432544Phase 1Unknown
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia comparing SHR-1918 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events (AEs) and Number of subjects with serious adverse events (SAEs). Status: unknown.
02
Drugs
SHR-1918
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05432544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432544.